BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, April 26, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Sep. 15, 2016
View Archived Issues
Kezar Life Sciences begins phase I study of its immunoproteasome inhibitor
Read More
Aphios obtains funding from NIAID to develop cure for HIV/AIDS
Read More
C3 may be useful as a biomarker to monitor ERT efficacy in Fabry disease
Read More
New transgenic model to assess target engagement of tau gene silencing therapies in live mice
Read More
Phase I data for CAR-modified T-cell immunotherapy in patients with non-Hodgkin's lymphoma
Read More
Azevan reports promising phase II data for SRX-246 in intermittent explosive disorder
Read More
Merck KGaA joins project to improve vaccine purification processes
Read More
FDA approves Shire's Cuvitru for primary immunodeficiency
Read More
Allele Biotechnology and Pharmaceuticals awarded SBIR grant from NHLBI
Read More
Neural Analytics receives NIH grant to develop brain diagnostic and monitoring platform
Read More
Launch of Relay Therapeutics with novel drug discovery platform focused on protein motion
Read More
Bayer and Monsanto sign definitive merger agreement
Read More
Aerie reports encouraging data from first registration trial of Roclatan
Read More
Allergan to acquire Vitae Pharmaceuticals and strengthen its dermatology product pipeline
Read More
Inhibikase Therapeutics cleared to conduct clinical studies of ABL inhibitors in Parkinson's disease
Read More
SELLAS Life Sciences enters CRADA to develop AML-MRD assay
Read More
Lenvatinib approved in E.U. for renal cell carcinoma
Read More
New gene silencing model confirms the XPO1 gene as a target for treating heart failure
Read More
KCa3.1 channel blockade shows promise as a therapeutic target in pulmonary fibrosis
Read More
FDA committee says studies of apaziquone do not show evidence of treatment effect
Read More
Bexion initiates phase I trial of BXQ-350 for advanced solid tumors
Read More
Basilea partners with Asahi Kasei Pharma for isavuconazole in Japan
Read More
Research indicates AQP1 as potential therapeutic target for pulmonary hypertension
Read More